Chi DS - Search Results

1

TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).

Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. Reuss A, et al. Among authors: chi ds. Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15. Int J Gynecol Cancer. 2019. PMID: 31420412

2

Splenectomy in recurrent epithelial ovarian cancer.

Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR. Gemignani ML, et al. Among authors: chi ds. Gynecol Oncol. 1999 Mar;72(3):407-10. doi: 10.1006/gyno.1998.5141. Gynecol Oncol. 1999. PMID: 10053114 Review.

3

Identification of prognostic factors in advanced epithelial ovarian carcinoma.

Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, Hoskins WJ. Chi DS, et al. Gynecol Oncol. 2001 Sep;82(3):532-7. doi: 10.1006/gyno.2001.6328. Gynecol Oncol. 2001. PMID: 11520151

4

Advanced ovarian cancer.

Chi DS, Sabbatini P. Chi DS, et al. Curr Treat Options Oncol. 2000 Jun;1(2):139-46. doi: 10.1007/s11864-000-0058-1. Curr Treat Options Oncol. 2000. PMID: 12057051 Review.

5

Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report.

Chi DS, Temkin SM, Abu-Rustum NR, Sabbatini P, Jarnagin WR, Blumgart LH. Chi DS, et al. Gynecol Oncol. 2002 Oct;87(1):138-42. doi: 10.1006/gyno.2002.6717. Gynecol Oncol. 2002. PMID: 12468355

6

Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.

Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. Sabbatini P, et al. Clin Cancer Res. 2004 May 1;10(9):2962-7. doi: 10.1158/1078-0432.ccr-03-0486. Clin Cancer Res. 2004. PMID: 15131031 Clinical Trial.

7

Surgical cytoreduction in ovarian cancer.

McCreath WA, Chi DS. McCreath WA, et al. Among authors: chi ds. Oncology (Williston Park). 2004 May;18(5):645-53, discussion 653-4, 656, 658. Oncology (Williston Park). 2004. PMID: 15209191 Free article. Review.

8

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR. Chi DS, et al. Gynecol Oncol. 2004 Sep;94(3):650-4. doi: 10.1016/j.ygyno.2004.01.029. Gynecol Oncol. 2004. PMID: 15350354

9

Tertiary cytoreduction in patients with recurrent ovarian carcinoma.

Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Leitao MM Jr, et al. Among authors: chi ds. Gynecol Oncol. 2004 Oct;95(1):181-8. doi: 10.1016/j.ygyno.2004.07.033. Gynecol Oncol. 2004. PMID: 15385129

10

The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.

Eitan R, Levine DA, Abu-Rustum N, Sonoda Y, Huh JN, Franklin CC, Stevens TA, Barakat RR, Chi DS. Eitan R, et al. Among authors: chi ds. Cancer. 2005 Apr 1;103(7):1397-401. doi: 10.1002/cncr.20920. Cancer. 2005. PMID: 15726548 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

485 results

Search Page

Filters